Biostage Inc (NASDAQ:BSTG) has been assigned a $3.00 target price by stock analysts at Maxim Group in a research note issued on Friday. The brokerage presently has a a “buy” rating on the stock. Maxim Group’s price target points to a potential upside of 172.73% from the stock’s previous close.

Shares of Biostage (NASDAQ:BSTG) traded down 13.455% during trading on Friday, reaching $0.952. 349,798 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $1.05 and its 200-day moving average price is $1.36. Biostage has a 52-week low of $0.53 and a 52-week high of $3.47. The stock’s market cap is $16.29 million.

Biostage (NASDAQ:BSTG) last issued its earnings results on Thursday, August 11th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.04. On average, equities research analysts forecast that Biostage will post ($0.86) EPS for the current year.

About Biostage

Biostage, Inc, formerly Harvard Apparatus Regenerative Technology, Inc, is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient’s own cells.

5 Day Chart for NASDAQ:BSTG

Receive News & Ratings for Biostage Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostage Inc and related companies with's FREE daily email newsletter.